SMi Source lesson Anticoagulation: Treatments II has the following microlearning topics
1. Introduction
2. Overview of Anticoagulant Agents
3. Limitations of Traditional Rapid Acting and Oral Anticoagulants
4. Development, Advantages and Limitations of Novel Oral Anticoagulants
5. Knowledge Check: Characteristics of Vitamin K Antagonists and Novel Oral Anticoagulants (NOACs)
6. Use of Anticoagulants and FDA Approved Novel Oral Anticoagulants
7. Stroke Prevention in Atrial Fibrillation
8. Venous Thromboembolism (VTE)
9. Acute Coronary Syndrome (ACS)
10. Knowledge Check: Anticoagulant Therapy for Atrial Fibrillation at High Risk
11. Knowledge Check: Anticoagulant Therapy for Atrial Fibrillation at Low Risk
12. Knowledge Check: Guidelines for Anticoagulant Extended Therapy for VTE
13. Use of Novel Oral Anticoagulants: Overview
14. Novel Oral Anticoagulant (NOAC) Targets
15. Dabigatran: Overview, Indications, Dosage and Administration
16. Direct Thrombin Inhibitors: Mechanism of Action and Clinical Pharmacology
17. Dabigatran: Special Considerations
18. Dabigatran: Contraindications, Warnings and Precautions
19. Dabigatran: Use in Pregnancy, Laboratory Monitoring and Anticoagulant Reversal
20. Rivaroxaban: Overview, Indications, Dosage and Administration
21. Rivaroxaban: Mechanism of Action and Clinical Pharmacology
22. Rivaroxaban: Special Considerations, Contraindications and Boxed Warning
23. Rivaroxaban: Warnings and Precautions
24. Rivaroxaban: Use in Pregnancy, Laboratory Monitoring and Anticoagulant Reversal
25. Apixaban: Overview, Dosage and Administration
26. Apixaban: Mechanism of Action and Clinical Pharmacology
27. Apixaban: Special Considerations
28. Apixaban: Contraindications and Boxed Warning
29. Apixaban: Warning and Precautions
30. Apixaban: Use in Pregnancy, Laboratory Monitoring and Anticoagulant Reversal
31. Knowledge Check: Novel Oral Anticoagulants (NOACs)
32. Emerging Factor Xa Inhibitors: Edoxaban and Betrixaban
33. Knowledge Check: Emerging Anticoagulants
34. Table of Agents for Review
